Clover Biopharma Begins Patient Dosing In Phase 1 Trial With Scb-2020S, A Potentially Broadly Protective Chimeric Covid-19 Vaccine Candidate
Clover Biopharmaceuticals, Ltd., A Global Clinical-Stage Biotechnology Company, Announced The First Participants Have Been Dosed In A Phase 1 Clinical Trial To Assess The Safety And Immunogenicity Of Several Formulations Of Scb-2020S. Scb-2020S Is A Second Generation, Potentially Broadly Protective Covid-19 Vaccine Candidate Based On A Chimeric Beta And Prototype Trimeric Sars-Cov-2 S-Protein, Preserving Potential Neutralization Epitopes Across Multiple Variants Of Concern (Vocs) Of Sars-Cov-2, Including Omicron. Clover Intends To Explore How The Scb-2020S Construct Could Further Expand The Breadth Of Vaccine-Induced Neutralizing Antibodies To Address The Existing And Potential New Variant Strains Of The Sars-Cov-2 Virus.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!